Manish Tandon joined Ensem Therapeutics in August 2024 as our Head of Business Development. Manish has more than 25 years of business development, alliance management, new product planning and drug development experience in the biotech and pharmaceutical industries. Previously, Manish served as InnoCare Pharmas’ Vice President of Business Development and Alliance Management, where he was responsible for consummating an outlicensing deal with Biogen and an inlicensing deal with Incyte. Prior to InnoCare, Manish was the Vice President and Head of Business Development, Alliance Management, New Product Planning and IP at ArQule Inc where he led the organization in their licensing and M&A activity. At ArQule, Manish played a key role in its acquisition by Merck in January 2020 and outlicensing of derazantinib. 

Manish holds a B.Sc. (Chemistry) from St. Stephen’s College, Delhi University, Ph.D. in Organic Chemistry from Brown University, completed his Post Doctoral Fellow at Cornell University and an MBA from Boston University.